Does One Size Fit All? Considerations for Incretin Use in Special Populations

About this session

Metabolic syndrome and obesity are increasingly prevalent among persons with liver disease, particularly in those with metabolic dysfunction–associated steatotic liver disease (MASLD). As hepatologists incorporate powerful incretin therapies into their treatment arsenal, understanding their optimal use in diverse and special populations becomes essential—and is the focus of this session.

Speakers

• TK

  Tatyana Kushner

  Weill Cornell Medicine

  Chair

• MR

  Mary E. Rinella

  The University of Chicago

  Speaker

• MS

  Monika Sarkar

  University of California, San Francisco

  Speaker

• 

  Mazen Noureddin

  Houston Methodist Hospital

  Speaker

• JD

  Jessica PE Davis

  Washington DC VA Medical Center

  Speaker